GLP-1

When Lilly linked up with Amylin in 2002, exenatide promised to be the first drug that stimulated insulin production and lowered blood sugar when the body needed it, a so-called GLP-1 therapy that avoided the dangerous drops in blood-sugar levels that can accompany traditional shots of insulin.

Amylin, Lilly End Ill-Fated Linkup Jonathan D. Rockoff 2011

When Lilly linked up with Amylin in 2002, exenatide promised to be the first drug that stimulated insulin production and lowered blood sugar when the body needed it, a so-called GLP-1 therapy that avoided the dangerous drops in blood-sugar levels that can accompany traditional shots of insulin.

WSJ.com: What's News US 2011

Pine nut oil contains pinolenic acid, a fatty acid that stimulates the body to produce two natural appetite suppressants: the hormones cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1).

The Flex Diet M.D. James Beckerman 2011

Essentially, PYY and GLP-1 suppressed their appetites.

Experts targeting obesity raise hope of drugs to stop us feeling hungry 2011

Pine nut oil contains pinolenic acid, a fatty acid that stimulates the body to produce two natural appetite suppressants: the hormones cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1).

The Flex Diet M.D. James Beckerman 2011

Lixisenatide is a so-called GLP-1 drug which could eventually join similar drugs from rivals such as Eli Lilly and Amylin's Byetta and Novo Nordisk 's Liraglutide.

Sanofi's Diabetes Drug Shows Promise Sten Stovall 2010

One is known as Glucagon-like peptide-1, or GLP-1, and the second is known as Peptide YY, or PYY.

Experts targeting obesity raise hope of drugs to stop us feeling hungry 2011

The drugs, similar to a hormone in the digestive track known as GLP-1, boost the production of insulin in order to regulate blood-sugar levels.

FDA Again Denies Approval for Long-Acting Byetta Thomas Gryta 2010

Then we gave them an infusion of GLP-1 and PYY and again showed them the pictures of food.

Experts targeting obesity raise hope of drugs to stop us feeling hungry 2011

Amid the rapid spread of diabetes, Novo Nordisk's earnings have grown steadily, driven by rising sales of treatments for the disease like insulins as well as the recently-launched Victoza, which belongs to the GLP-1 analogue drug class and compared with insulin doesn't risk pushing blood sugar too low.

Diabetes Drugs Aid Nordisk Profit Gustav Sandstrom 2010